Figure 10

Immunosuppression of UCX® and UCX®-ATMP. (A) Suppression of T cell activation was assayed by incubating CD3, CD28 and IL2 activated peripheral blood mononucleated cells (PBMCs) from two different donors with irradiated UCX® and UCX®- advanced therapy medicinal product (ATMP) and measuring lymphocyte proliferation (B) Treg conversion was measured in the same cells by culturing irradiated cells with CD3⁺CD4⁺CD25^- T-cells and comparing the percentage of converted CD3⁺CD4⁺CD25⁺Foxp3⁺ regulatory T-cells with unstimulated cells (negative control) or induced conversion with TGFβ. Results are represented as mean ± SEM.